Last Updated : April 19, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status Sort descending | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Brilinta | Ticagrelor | Acute Coronary Syndromes | Cancelled | |||
| Twynsta | Telmisartan / Amlodipine | Hypertension | Cancelled | |||
| BuTrans | Buprenorphine transdermal patch | Pain, persistent (moderate intensity) | Cancelled | |||
| Targin | Oxycodone / naloxone | Pain, Moderate to severe and relief of opioid-induced constipation | Cancelled | |||
| Keytruda | Pembrolizumab | classical Hodgkin Lymphoma (cHL) | Reimburse with clinical criteria and/or conditions | Complete | ||
| Spinraza | nusinersen | Spinal Muscular Atrophy | Reimburse with clinical criteria and/or conditions | Complete | ||
| Procysbi | cysteamine bitartrate | Nephropathic cystinosis | Reimburse with clinical criteria and/or conditions | Complete | ||
| Venclexta | Venetoclax | Chronic Lymphocytic Leukemia | Reimburse with clinical criteria and/or conditions | Complete | ||
| Movapo | apomorphine hydrochloride | Parkinson's disease | Reimburse with clinical criteria and/or conditions | Complete | ||
| Lartruvo | Olaratumab | Advanced Soft Tissue Sarcoma | Reimburse with clinical criteria and/or conditions | Complete |
Last Updated : April 19, 2024